FDA Approval for Surgimesh WN
In 2006 the FDA approved SURGIMESH WN for use in the treatment of hernias. The FDA’s decision turned SURGIMESH WN into the first non-woven, polypropylene mesh approved for surgical hernia treatment in the U.S. The product is now available for the more than 1 million patients who receive surgical hernia treatments in the United States each year.
SURGIMESH WN stands out from other implant meshes because it is made of an innovative, non-woven, microfiber biomaterial. The randomized, nonwoven polypropylene microfibers used to create SURGIMESH WN showed significant advantages over other products in clinical trials. This unique biomaterial that minimizes chronic patient pain, allows more comfortable recoverys, and creates fewer post-operative complications. Patients who receive SURGIMESH WN, therefore, can heal more quickly than other patients and experience less discomfort related to the hernia repair.
Aspide Medical
The innovative biomaterial used to make SURGIMESH WN was created by Aspide Medical, a French company that has worked in the medical manufacturing industry for more than 15 years. SURGIMESH WN is only one of the company’s numerous successes. It has also created breakthrough products in healthcare markets. Some Aspide Medicals top innovations include products for digestive, urologic, aesthetic, and gynecologic surgeries. Patients and doctors can learn more about Aspide Medical by visiting the company’s web site at http://aspide.com.
BG Medical
SURGIMESH WN’s success with patients in the United States largely comes from the marketing expertise of BG Medical. BG Medical focuses on sales and marketing distribution partnerships with companies, such as Aspide Medical, that create innovative, next-generation products. BG Medical has a variety of core competencies that include urogynecologic, thoracic, colorectal, general and laparoscopic specialty surgery, and other emerging, minimally invasive platform applications that can benefit patients and doctors. BG Medical’s level of success in these areas has won it exclusive US distribution rights for SURGIMESH WN and other medical device technologies.